Shining a light on the dark Nt-acetylome by integrating omics data

By integrating extensive COFRADIC proteomics with the high-sensitivity sel-TRAP approach, this study constructs the most comprehensive map of the human and yeast Nt-acetylomes to date, revealing refined Nat substrate specificities and uncovering hundreds of previously hidden cryptic substrates generated by alternative translation initiation.

The Gist

The Big Picture: The "Dark" Side of Protein Labels

Imagine your body is a massive, bustling factory. Inside, machines called ribosomes are constantly building products (proteins) based on blueprints (DNA).

As soon as a new product starts coming off the assembly line, a special team of workers called N-terminal Acetyltransferases (Nats) rushes in to slap a sticker on the very first part of the product. This sticker is called N-terminal acetylation.

Why do they do this?

• It changes how the product folds up.
• It decides where the product goes in the factory (the nucleus, the mitochondria, etc.).
• It determines how long the product lasts before being recycled.

For a long time, scientists thought they had a pretty good map of which products got these stickers. But this paper argues that we've only been looking at the "brightly lit" part of the factory floor. There is a massive "Dark Nt-acetylome"—a hidden world of proteins and protein variations that we've been missing.

The Problem: We Were Only Looking at the Top 10%

The researchers explain that previous studies used a method called COFRADIC (a fancy way of saying "sorting proteins by weight and size") to find these stickers. But this method is like trying to study a forest by only looking at the tallest, most visible trees. It missed the small saplings and the ones hidden in the shade.

• The Stat: They found that previous studies had only identified stickers on about 5–10% of all proteins.
• The Result: We were missing the vast majority of the "dark" acetylome.

The Solution: Two Tools, One Big Map

To fix this, the team combined two different detective tools:

1. The Old Tool (COFRADIC): They gathered all the existing data from the last decade (like collecting all the old photos of the factory) to get a bigger, clearer picture of the "tall trees."
2. The New Tool (sel-TRAP): This is the game-changer. Imagine putting a magnet on the assembly line workers (the ribosomes) to pull out the very first products they are making, even if those products are tiny, rare, or get moved to a different room immediately. This allowed them to catch proteins that the old method missed, especially those destined for the mitochondria (the factory's power plants).

The Big Discovery: "Secret Identities" and "Alternative Start Lines"

The most exciting part of the paper is the discovery of Cryptic Substrates.

Think of a protein blueprint like a movie script. Usually, the movie starts at Scene 1. But sometimes, the ribosome (the director) decides to skip the first few scenes and start filming at Scene 2 or Scene 3. This creates a slightly different version of the movie, called an Alt-start proteoform.

• The Surprise: These "alternative start" versions have different first letters (N-termini) than the main version.
• The Consequence: Because the first letter is different, a different sticker team (Nat) might show up to label it.
• The Impact: A single gene can produce multiple versions of a protein, some with stickers, some without, some going to the nucleus, some staying in the cytoplasm.

The Fumarase Example (The Star of the Show):
The paper uses a protein called Fumarase to illustrate this.

• Version A (The Main Character): Starts at the beginning, gets a specific sticker, and goes to the mitochondria to do its job.
• Version B (The Truncated Hero): Starts a little later (skipping the first 24 steps). It doesn't have the "mitochondria ticket," so it stays in the main factory floor or goes to the nucleus to help fix DNA damage.
• The Twist: The researchers found that this "Truncated Hero" gets a different sticker than the main character. This changes how long it lives and what it does.

Why Does This Matter?

1. It's More Complex Than We Thought: We used to think one gene = one protein with one sticker. Now we know one gene = many protein versions, each with its own unique sticker and job.
2. Human Disease: In humans, this "dark" world is even bigger. We have more sticker teams (Nats) and more ways to start the assembly line. If these stickers go wrong, it can lead to cancer, neurodegenerative diseases, or developmental syndromes.
3. The Future: We are currently blind to about 90% of the human protein "sticker" landscape. To understand diseases and how our cells really work, we need better tools to shine a light on this dark corner.

Summary Analogy

Imagine you are trying to understand a city's traffic system.

• Old Method: You only counted the big buses and trucks on the main highway. You thought you knew where everything was going.
• New Method: You realized there are thousands of delivery vans, scooters, and secret underground tunnels (the "Dark Nt-acetylome") that you completely missed.
• The Discovery: You found out that some drivers are taking "shortcut routes" (Alternative Starts) that change their destination entirely. A driver who was supposed to go to the bank (Mitochondria) might actually end up at the library (Nucleus) because they started their trip two blocks later.

This paper is the first major map of those secret shortcuts and hidden vehicles, proving that the city (our cells) is much more chaotic and fascinating than we ever imagined.

Technical Summary

1. Problem Statement

Protein N-terminal acetylation (NTA) is a ubiquitous and irreversible post-translational modification catalyzed by N-terminal acetyltransferases (Nats). While NTA is known to regulate protein folding, stability, localization, and degradation, and is implicated in human diseases (cancer, neurodegeneration), the full scope of the "Nt-acetylome" remains largely unexplored.

• Limitations of Current Data: Previous studies relying on Nt-COFRADIC (Combined Fractional Diagonal Chromatography) proteomics have only interrogated ~5–10% of the proteome. This limited coverage creates a "dark" Nt-acetylome where many substrates, particularly those with low abundance or unconventional N-termini, remain undetected.
• Predictive Gaps: Existing models of Nat substrate specificity (NatA, NatB, NatC) are based on limited datasets, making it difficult to reliably predict acetylation status for the majority of proteins, especially those with partial acetylation or unconventional initiator methionine (iMet) retention.
• Hidden Complexity: The existence of alternative translation initiation (Alt-start) events, which generate cryptic N-terminal proteoforms with distinct acetylation patterns, has been largely overlooked in standard proteomic analyses.

2. Methodology

The authors employed a multi-omics integration strategy to overcome the sensitivity and coverage limitations of traditional proteomics:

• Meta-Analysis of COFRADIC Data:

  • Aggregated five major Nt-COFRADIC datasets for S. cerevisiae (yeast) and H. sapiens (human).
  • Analyzed N-terminal acetylation levels (NTA %) across wild-type and Nat-perturbed conditions (knockouts, knockdowns, or ectopic expression) to refine substrate specificities.
  • Calculated confidence intervals for acetylation frequencies to assess the reliability of extrapolating findings to the whole proteome.

• Integration of sel-TRAP (Selective Translating Ribosome Affinity Purification):

  • Utilized a high-sensitivity, orthogonal approach in yeast to immunoprecipitate ribosomes associated with NatA, NatB, and NatC.
  • Captured co-translating nascent chains and their corresponding mRNAs, which were then profiled via microarray.
  • This method detects Nat targets based on affinity during translation, capturing low-abundance proteins (e.g., mitochondrial precursors) that are often missed by mass spectrometry.

• Statistical & Computational Analysis:

  • Ridgeline Plots: Visualized global acetylation distributions and individual peptide levels.
  • Confidence Scoring: Assigned confidence scores (0–1) to substrate specificities based on COFRADIC acetylation rates, sel-TRAP enrichment, and in vitro literature.
  • Alt-Start Detection: Systematically searched for peptides originating from methionines within the first 50 amino acids downstream of the annotated start codon to identify cryptic proteoforms.

3. Key Contributions

• Comprehensive Substrate Inventory: Created the most extensive list of Nat substrates to date, identifying 1,145 canonical targets in yeast and 1,683 in humans.
• Refined Specificity Models: Updated the substrate specificity rules for NatA, NatB, and NatC, particularly revealing extended specificities for NatC (e.g., MH- and MQ- N-termini when followed by Arginine at position 3).
• Discovery of the "Dark" Nt-acetylome: Quantified the "dark" portion of the acetylome, demonstrating that many substrates are missed due to low abundance, partial acetylation, or unconventional iMet retention.
• Identification of Cryptic Substrates: Uncovered 104 cryptic Nat substrates in yeast and 123 in humans arising from alternative translation initiation, which generate N-terminal proteoforms with distinct acetylation statuses.

4. Key Results

A. Quantitative Insights into Nat Specificities

• NatA: Highly specific for S-, A-, T-, G-, and V- N-termini (after iMet removal). Human NatA shows higher efficiency and acetylation levels than yeast NatA.
• NatB: Targets iMet followed by D, N, E, or Q. The study confirmed high affinity for MD- and MN- but lower/variable affinity for MQ-.
• NatC: Traditionally known for large hydrophobic residues (F, L, I, W, M, Y). The study revealed that NatC also targets MH- and MQ- N-termini, provided an Arginine is present at position 3.
• Human vs. Yeast Differences: Humans exhibit higher rates of unconventional iMet retention (e.g., MT-, MG-, MV-), likely due to the presence of additional Nats (NatE, NatF) that compete with Methionine Aminopeptidases (MetAPs). This leads to a more complex landscape of iMet-acetylated proteoforms in humans.

B. The "Dark" Nt-acetylome and Alt-Starts

• Coverage Gap: Even with integrated datasets, COFRADIC covers only ~19% of the yeast proteome and ~9% of the human proteome.
• Cryptic Targets: The sel-TRAP analysis identified hundreds of mRNAs enriched in Nat IPs that did not match canonical N-termini. Re-analysis revealed these correspond to alternative translation start sites.
  • Example: The mitochondrial protein MRP13 has an annotated MG- N-terminus (NatA), but an alternative start at Met28 generates an MFR- N-terminus (NatC), explaining its high enrichment in NatC sel-TRAP data.
• Dual Localization: Many Alt-start proteoforms lack the N-terminal Mitochondrial Targeting Sequence (MTS), resulting in cytoplasmic or nuclear localization.
  • Case Study (Fumarase/Fum1): The study proposes a model where Fum1 exists in three forms:
    1. Fum1(1–488): Precursor with MTS, NatC substrate (acetylated).
    2. Fum1(25–488): Mature mitochondrial form (MTS cleaved), unacetylated.
    3. Fum1(24–488): Alt-start truncated form lacking MTS, NatB substrate (acetylated), likely cytoplasmic/nuclear.
  • These distinct proteoforms may have different stabilities (via the N-end rule pathway) and functions.

C. Human Implications

• In humans, less than 10% of canonical isoforms have been profiled. The study identified 123 human cryptic substrates from Alt-starts.
• The presence of NatE and NatF in metazoans expands the scope of iMet acetylation, creating a more diverse and "darker" acetylome compared to yeast.

5. Significance

• Conceptual Shift: The paper challenges the view of proteins as single entities with a fixed N-terminus, highlighting that N-terminal proteoform diversity (driven by Alt-starts and variable acetylation) is a major regulatory layer.
• Methodological Advancement: Demonstrates that integrating transcriptomic (sel-TRAP) and proteomic (COFRADIC) data is essential to map the full Nt-acetylome, as proteomics alone misses low-abundance and rapidly processed targets.
• Biological & Clinical Relevance:
  • Provides a mechanistic basis for how alternative translation initiation can alter protein localization (e.g., mitochondrial vs. cytoplasmic) and stability.
  • Highlights that the "dark" Nt-acetylome is a significant blind spot in understanding human diseases (cancer, neurodegeneration) where NTA dysregulation is a known factor.
  • Calls for new, more sensitive experimental approaches to systematically characterize the full diversity of human N-terminal proteoforms.

In conclusion, this study moves beyond the canonical view of N-terminal acetylation, revealing a complex, dynamic, and largely unexplored landscape of protein regulation driven by alternative translation and enzyme competition.